Page 70 - D. Cancer biology

[D. Cancer biology-49]

CDKN2A/p16 is a potential novel biomarker for predicting

prognosis in hepatocellular carcinoma

Baeki E Kang¹˙#, Jeongho Kwon¹˙#, Dongryeol Ryu¹

¹Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Suwon 16419, Republic of

Korea

Hepatocellular carcinoma (HCC) currently accounts for around 90% of all diagnosed liver cancers and ranks second
as the cause of cancer fatality in South Korea. Early diagnosis is of huge importance for HCC to be cured completely.

With no doubt, it is crucial to discover a valid prognostic marker for early diagnosis of HCC. In this study, we sought

to distinguish if the expression of CDKN2A/p16INK4A, a famous cell cycle regulating protein and a marker of cellular
senescence, could be a valid prognostic marker for HCC. The observation of survival rate of HCC patients with high
p16INK4A expression is significantly lower than other HCC patients suggests CDKN2A/p16INK4A could have a

crucial role in the progression of HCC and be a novel prognostic marker for HCC.